Lymphoma

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Electronic symptom self-measuring provided early detection of toxic effects and helped anticipate necessary medical interventions for pediatric patients with cancer.

Case management programs or pharmacist-delivered high-touch care are critical components in medical specialty drug management.

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

Progression-free survival was longer with brentuximab vedotin and fewer patients with Hodgkin lymphoma in this group received subsequent therapy.

Pursuing the expanded access process for treatment may be the best option for patients who have exhausted all available FDA-approved drugs and clinical trials.

Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.

Clinical trial results show durable responses with mosunetuzumab in advanced follicular lymphoma.

This month, we reviewed key topics and interviews from the American Society of Clinical Oncology 2022 Annual Meeting.

Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.

The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.

JZP458, a recombinant Erwinia-derived ASNase from a Pseudomonas fluorescens expression platform, was previously approved by the FDA for patients with ALL/LBL who had developed hypersensitivity to Escherichia coli (E. coli)–derived ASNase.

Overall, the investigators observed that the CR, undetectable minimal residual disease rates, progression free survival, and overall survival amomg the patients enrolled in the trial were favorable.

The trial achieved a complete remission rate of 39.4%, which researcher Michael Dickinson, MBBS, DMedSci, called "remarkable."

Three-year follow-up analysis shows that Gilead’s car T-cell therapy induced high rates of durable response and a median overall survival of 46.6 months.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Tisagenlecleucel was shown to be effective in high-risk patients, including those who were heavily pretreated or had refractory disease.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses where she sees the classification of lymphoma progressing in the coming years.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses points of note in the evolution of lymphoma classification during her clinical and investigational research on the subject.

Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.